Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Non-Current Assets for 12 consecutive years, with $24.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 102.51% to $24.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Dec 2025, up 102.51% year-over-year, with the annual reading at $24.9 million for FY2025, 102.51% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $24.9 million at Theravance Biopharma, up from $836000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $24.9 million in Q4 2025, with the low at $833000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $5.0 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets tumbled 93.09% in 2024, then skyrocketed 1553.59% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $3.2 million in 2021, then tumbled by 74.1% to $836000.0 in 2022, then changed by 0.0% to $836000.0 in 2023, then skyrocketed by 1369.62% to $12.3 million in 2024, then skyrocketed by 102.51% to $24.9 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $24.9 million, $836000.0, and $836000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.